Geron

Geron Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Geron (GERN) as of Nov 6, 2026 is 8,106.08. In the previous year, Cash Conversion Cycle (CCC) was 8,923.14 — a change of -9.16% (lower).

Cash Conversion Cycle

8,106.08

YoY

-9.16%

Last updated:

Cash Conversion Cycle (CCC) of Geron is 2025 8,106.08 . Cash Conversion Cycle (CCC) of Geron was 2024 8,923.14 . It decreases by -9.16% lower compared to the previous year.

The Geron Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-61.68 USD
Jan 1, 2019
-18.43 USD
Jan 1, 2020
-55.72 USD
Jan 1, 2021
-3,769.34 USD
Jan 1, 2022
-5,607.04 USD
Jan 1, 2023
-18.17 USD
Jan 1, 2024
8,923.14 USD
Jan 1, 2025
8,106.08 USD
The Geron Cash Conversion Cycle history
YEARCash Conversion CycleYoY
8,106.08-9.16%
8,923.14-49,200.26%
-18.17-99.68%
-5,607.04+48.75%
-3,769.34+6,664.62%
-55.72+202.27%
-18.43-70.11%
-61.68+51.83%
-40.62+133.64%
-17.39-66.61%
-52.08-36.37%
-81.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geron stock

Cash Conversion Cycle (CCC) of Geron is 8,106.08 in 2025.

Cash Conversion Cycle (CCC) of Geron changed from 8,923.14 to 8,106.08, representing a -9.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Geron since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Geron with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Geron

All Key Metrics — Geron